Satellos Bioscience Inc.

TSX:MSCL.TO

Biotechnology

Healthcare
$8.62 +0.12%

+$0.01 today

Market cap
$182.89M
Beta
1.17
P/E (TTM)
-1.8
EPS (TTM)
-$0.32
52W Low $6.36High $18.98

Volume 0.01M

Average 0.02M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$24.01M

FY 2025 · Annual

Investing Cash Flow

-$9.58M

FY 2025 · Annual

Financing Cash Flow

$2.28M

FY 2025 · Annual

-95.7% YoY

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · CAD
FY2024
Dec 2024 · CAD
FY2025
Dec 2025 · USD
Net Income(15.51M)(11.32M)(15.89M)(28.1M)(25.31M)
Depreciation & Amortization165.69K337K7K20K4K
Deferred Income Tax00000
Stock-Based Compensation971.53K1.44M2.17M2.11M3.24M
Change in Working Capital(485.64K)991K369K(1.03M)(1.5M)
Accounts Receivables(67.4K)267.55K(323K)(43K)66.14K
Inventory00000
Accounts Payables(390.47K)726.11K000
Other Working Capital(27.77K)(1.93K)692K(982K)(1.57M)
Other Non-Cash Items9.82M2.91M(1.07M)2.02M(435.77K)
Operating Cash Flow(5.03M)(5.78M)(14.5M)(24.98M)(24.01M)
Capital Expenditures(7.25K)(3K)(18K)(6K)(6.1K)
Acquisitions (Net)1.75M0000
Purchases of Investments00(17.52M)(37.34M)(23.78M)
Sales of Investments00043.68M14.2M
Other Investing Activities00000
Investing Cash Flow1.74M(3K)(17.54M)6.34M(9.58M)
Debt Repayment186.57K0(284K)00
Common Stock Issued7.08M2.78M32.46M42.8M2.28M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities185.46K018.85M10.68M0
Financing Cash Flow7.45M2.78M51.03M53.49M2.28M
Effect of Forex Changes(1.44K)(76K)1.15M744K(890.45K)
Net Change in Cash4.15M(2.95M)20.14M35.59M(32.2M)
Free Cash Flow(5.04M)(5.79M)(14.52M)(24.98M)(24.02M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$25.3M
+ D&A$4.0K
+ Stock-Based Comp$3.2M
+ Deferred Tax$0
- Working Capital-$1.5M
- Other Non-Cash-$435.8K
= Operating Cash Flow-$24.0M
- Capex-$6.1K
= Free Cash Flow-$24.0M

Analysis

FY2025 free cash flow is -$24.0M. FCF conversion is 94.9% of net income. Operating cash flow was -$24.0M, with capex of -$6.1K. The largest bridge item is Stock-Based Comp at $3.2M.

Recent Filings

Recent regulatory filings

No filings found.

Does MSCL.TO generate free cash flow?

Satellos Bioscience Inc. (MSCL.TO) generated -$24.02M of free cash flow in fiscal 2025.

How much operating cash flow does MSCL.TO produce?

Operating cash flow was -$24.01M, before capital expenditures of $6,101.00.